Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BTCY 
Biotricity Inc (BTCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/09/2025: BTCY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.21% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.57M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.13 | 52 Weeks Range 0.22 - 0.83 | Updated Date 10/17/2025 |
52 Weeks Range 0.22 - 0.83 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.33% | Operating Margin (TTM) 7.28% |
Management Effectiveness
Return on Assets (TTM) -11.46% | Return on Equity (TTM) -4100.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42888207 | Price to Sales(TTM) 1.15 |
Enterprise Value 42888207 | Price to Sales(TTM) 1.15 | ||
Enterprise Value to Revenue 2.97 | Enterprise Value to EBITDA -3.76 | Shares Outstanding 26567769 | Shares Floating 13982182 |
Shares Outstanding 26567769 | Shares Floating 13982182 | ||
Percent Insiders 39.37 | Percent Institutions 1.86 |
Upturn AI SWOT
Biotricity Inc
Company Overview
History and Background
Biotricity Inc. was founded with the goal of providing innovative and accessible remote patient monitoring solutions. Specific founding year and early milestones require further research due to limited readily available public information.
Core Business Areas
- Remote Patient Monitoring (RPM) Solutions: Development and commercialization of medical-grade wearable sensors and software platforms for remote monitoring of chronic conditions, including cardiac health.
Leadership and Structure
Details on the current leadership team and specific organizational structure are not readily available without deeper research. Publicly available information is limited.
Top Products and Market Share
Key Offerings
- Bioflux: A remote cardiac monitoring solution designed for patients with heart conditions. Market share data is not readily available. Competitors include iRhythm Technologies (IRTC) and Preventice Solutions (acquired by Boston Scientific).
Market Dynamics
Industry Overview
The remote patient monitoring (RPM) market is experiencing significant growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in wearable technology. Telehealth solutions are gaining wider acceptance.
Positioning
Biotricity aims to carve a niche in the RPM market by providing user-friendly and cost-effective remote monitoring solutions. Competitive advantages would stem from technology innovation and data analytics capabilities.
Total Addressable Market (TAM)
The global remote patient monitoring market is expected to reach billions of dollars. Biotricity's position within this TAM is dependent on its market penetration and product adoption rates. Precise figures for TAM require further market analysis.
Upturn SWOT Analysis
Strengths
- Potential for innovative remote patient monitoring technology
- Focus on cardiac health monitoring
- Scalable business model
Weaknesses
- Limited market presence compared to larger competitors
- Reliance on funding for continued development and commercialization
- Uncertain regulatory landscape
Opportunities
- Expanding adoption of telehealth and remote patient monitoring
- Partnerships with healthcare providers and payers
- Development of new RPM applications for other chronic conditions
Threats
- Competition from established medical device companies
- Rapid technological advancements
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- IRTC
Competitive Landscape
Biotricity faces significant competition from larger, more established companies in the RPM market. Its advantages lie in innovation and potential for specialized solutions, but it needs to overcome challenges related to funding and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would require access to revenue and other financial data over time.
Future Projections: Future growth projections are dependent on analyst estimates, which are not widely available for Biotricity. Potential growth drivers include expanding product adoption and securing partnerships.
Recent Initiatives: Recent initiatives requires monitoring press releases and company announcements. Focus on strategic partnerships, product development, and sales & marketing initiatives.
Summary
Biotricity Inc. is a small company operating in a competitive remote patient monitoring market. Its future success depends on securing funding, developing innovative products, and gaining market share against larger competitors. Its weak financial performance and heavy dependence on external funding raise concerns. However, growing demand for RPM solutions presents opportunities for growth if they can execute their strategy well.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Public filings
- Press releases
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. The remote patient monitoring market is dynamic and competitive, and future performance is uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biotricity Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2016-02-18 | Founder, President, CEO & Chairman Dr. Waqaas Al-Siddiq Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 46 | Website https://www.biotricity.com |
Full time employees 46 | Website https://www.biotricity.com | ||
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare which support medical practitioners to gather data, and regularly monitor and treat patients with two or more chronic care conditions; Bioheart that offers preventative care and disease management solutions; and Biokit, a remote patient monitoring kit for cardiac patients that had other chronic conditions such as hypertension or COPD. Biotricity, Inc. is based in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.